Rhythm Pharmaceuticals Inc. Common Stock (RYTM)
Stock · NASDAQ · Health Care
$86.19as of 10/16/2026
Price chart
Active signals
RYTM Signal Track Record
How signals performed across all stocks →What RYTM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 32 | -1.6% | 47% | August 7, 2026 |
| Volume Spike | 30 | +1.4% | 60% | September 14, 2026 |
| Bollinger Band Breakdown | 14 | +2.3% | 50% | October 7, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +6.9% | 67% | September 17, 2026 |
| Any 20-session window (baseline) | +1.9% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alst…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 414
- Website
- rhythmtx.com/
Fundamentals
- 1-day range
- $85.91$88.62
- Market cap
- $7.72B
- P/E (trailing)
- —
- P/E (forward)
- -137.05
- EPS (trailing)
- $-3.05
- Dividend yield
- —
- Beta
- 2.13
- Avg. volume
- 672.9K
How Rhythm Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
18 analyst ratings
Rhythm Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RYTMRhythm Pharmaceuticals Inc. Common Stock$86.17▼ 2.05%Market cap $7.72BP/E —$74.5$122.2
- TGTXTG Therapeutics Inc. Common Stock$53.97▼ 3.62%Market cap $7.59BP/E 19.42$26.76$59.3
- LQDALiquidia Corporation Common Stock$34.35▼ 1.24%Market cap $7.95BP/E 22.46$21.94$93.61
- ALKSAlkermes plc Ordinary Shares$41.22▲ 2.79%Market cap $8.11BP/E 99.15$27$55.67
- COGTCogent Biosciences Inc. Common Stock$29.52▲ 0.03%Market cap $7.14BP/E —$13.78$43.73
- IONSIonis Pharmaceuticals Inc. Common Stock$42.94▼ 2.67%Market cap $9.06BP/E —$42.08$86.74
- BLTEBelite Bio Inc American Depositary Shares$142.78▼ 6.45%Market cap $6.32BP/E —$78.71$200
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals Inc. Common Stock | $7.72B | — | $86.17 | ▼ 2.05% | $74.5$122.2 |
| TGTX TG Therapeutics Inc. Common Stock | $7.59B | 19.42 | $53.97 | ▼ 3.62% | $26.76$59.3 |
| LQDA Liquidia Corporation Common Stock | $7.95B | 22.46 | $34.35 | ▼ 1.24% | $21.94$93.61 |
| ALKS Alkermes plc Ordinary Shares | $8.11B | 99.15 | $41.22 | ▲ 2.79% | $27$55.67 |
| COGT Cogent Biosciences Inc. Common Stock | $7.14B | — | $29.52 | ▲ 0.03% | $13.78$43.73 |
| IONS Ionis Pharmaceuticals Inc. Common Stock | $9.06B | — | $42.94 | ▼ 2.67% | $42.08$86.74 |
| BLTE Belite Bio Inc American Depositary Shares | $6.32B | — | $142.78 | ▼ 6.45% | $78.71$200 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Ratingbenzinga · 10/16/2026
- RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159Benzinga · 10/8/2026
- Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 YearsBenzinga · 10/8/2026
- Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic ObesityYahoo · 9/22/2026
- Rhythm Pharmaceuticals Receives Health Canada Approval Of IMCIVREE For Additional Indication Of Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With Acquired Hypothalamic ObesityBenzinga · 9/22/2026
- Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?Yahoo · 9/18/2026
- Tracking Baker Brothers' Portfolio: Q2 2026 UpdateSeekingAlpha · 9/16/2026
- Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- 10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 9/11/2026
Insider Activity
Insider Actions →- David P. Meeker · September 14, 2026 · Sale1.8K @ $104.55
- David P. Meeker · September 14, 2026 · Sale8.7K @ $103.43
- David P. Meeker · September 14, 2026 · Sale30.7K @ $102.35
- David P. Meeker · September 14, 2026 · Sale6.4K @ $101.75
- David P. Meeker · September 14, 2026 · Option Exercise50.0K @ $6.05
- David P. Meeker · September 14, 2026 · Sale2.3K @ $105.19
- Hunter C. Smith · August 31, 2026 · Option Exercise57.2K @ $25.79
- Hunter C. Smith · August 31, 2026 · Sale28.2K @ $106.2
- Hunter C. Smith · August 31, 2026 · Sale11.5K @ $105.37
- Hunter C. Smith · August 31, 2026 · Sale23.1K @ $104.59
- Joshi Manher · August 17, 2026 · Grant25.0K
- Joshi Manher · August 17, 2026 · Grant50.0K
- Joseph Shulman · August 13, 2026 · Option Exercise2.0K @ $6.8
- Joseph Shulman · August 13, 2026 · Sale5.1K @ $119.75
- Alastair Garfield · August 13, 2026 · Sale800 @ $119.17
Institutional Ownership
March 31, 2026
- Total shares held
- 68.63M
- Total value held
- $5.82B
- Institutional holders
- 279
- Unknown6.67M
- Unknown6.24M
- Unknown5.60M
- Unknown3.42M
- Unknown2.97M
- Unknown2.37M
- Unknown2.27M
- Unknown1.97M
- Unknown1.93M
- Unknown1.69M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RYTM: RBC raises price target to $159, maintains Outperform
RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.
RYTM: RBC raises price target to $159, maintains Outperform. RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.